filings.toolsItem 1A. RISK FACTORS
3K characters. Original on sec.gov · Markdown
Item 1A. RISK FACTORS
There have been no material changes from the risk factors disclosed in our annual report on Form 10-K for the year December 31, 2021. However, to the extent the Russia-Ukraine conflict or the COVID-19 pandemic adversely affect our business, financial condition, results of operations, and liquidity, they may also have the effect of heightening many of the other risks described in such risk factors.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
*(a)*Unregistered Sales of Equity Securities. Not applicable.
*(b)*Use of Proceeds. Not applicable.
*(c)*Issuer Purchases of Equity Securities. The following table discloses purchases of shares of our common stock made by us or on our behalf during the first quarter of 2022.
| Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Not Purchased as Part of Publicly Announced Plans or Programs (a) | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (b) | |||||||||||||||||||||||||||
| January 2022 | 126,802 | $ | 82.97 | 126,802 | — | $1.4 billion | ||||||||||||||||||||||||||
| February 2022 | 82,074 | $ | 86.45 | 82,074 | — | $1.4 billion | ||||||||||||||||||||||||||
| March 2022 | 1,336,997 | $ | 94.18 | 2,447 | 1,334,550 | $1.2 billion | ||||||||||||||||||||||||||
| Total | 1,545,873 | $ | 92.85 | 211,323 | 1,334,550 | $1.2 billion |
(a)The shares reported in this column represent purchases settled in the first quarter of 2022 relating to our purchases of shares from our employees and non-employee directors in connection with the exercise of stock options, the vesting of restricted stock, and other stock compensation transactions in accordance with the terms of our stock-based compensation plans.
(b)On January 23, 2018, we announced that our Board authorized our purchase of up to $2.5 billion of our outstanding common stock, with no expiration date. As of March 31, 2022, we had $1.2 billion remaining available for purchase under this program.
Previous: Item 4. CONTROLS AND PROCEDURES · Next: Item 6. EXHIBITS